Kirjojen hintavertailu – 12 903 725 kirjaa ja 27 kauppaa

Kirjailija

Julie Sheppard

Kirjat ja teokset yhdessä paikassa: 5 kirjaa, julkaisuja vuosilta 1999–2019, suosituimpiin kuuluu The Therapeutic Nightmare. Vertaile teosten hintoja ja tarkista saatavuus suomalaisista kirjakaupoista.

5 kirjaa

Kirjojen julkaisuvuodet: 1999–2019.

First Healthcare Compliance The Fundamentals, Second Edition

First Healthcare Compliance The Fundamentals, Second Edition

Julie Sheppard; Sheba Vine

First Healthcare Compliance
2019
nidottu
First Healthcare Compliance The Fundamentals, Second Edition is a comprehensive resource designed to help physicians, compliance professionals and other healthcare professionals in private practice, hospital networks and health systems, healthcare billing companies and skilled nursing facilities comply with federal rules and regulations and to better understand their compliance responsibilities at a time of heightened scrutiny and increased regulations. The book addresses the four major areas of healthcare compliance regulations: HIPAA, OSHA, federal waste and abuse laws, and federal employment laws. It can be used as a stand-alone resource or as a companion guide to the First Healthcare Compliance The Fundamentals online course.
First Healthcare Compliance HIPAA Privacy and Security

First Healthcare Compliance HIPAA Privacy and Security

Julie Sheppard; Sheba Vine

First Healthcare Compliance
2019
nidottu
First Healthcare Compliance HIPAA Privacy and Security is a user-friendly resource designed to help healthcare, administrative, and compliance professionals, whether they serve as a covered entity or a business associate, better understand their compliance responsibilities under the Health Insurance Portability and Accountability Act. The book explains HIPAA privacy, security, enforcement and breach notification in plain language, and provides a comprehensive checklist that entities can use to get their compliance efforts off the ground.
Consuming Passion (RLE Retailing and Distribution)

Consuming Passion (RLE Retailing and Distribution)

Carl Gardner; Julie Sheppard

Routledge
2012
sidottu
Britain’s high street revolution has made retailing one of the most important and dynamic sectorsof the British economy in the last twenty years. It has had an irreversible impact on our towns and cities and, for many people, transformed shopping from an unattractive domestic chore to a pleasurable ‘leisure ‘experience’, offering consumers an everchanging array of ‘disposable dreams’. The resulting ‘retail culture’ is everywhere – it has colonised huge areas of our social life outside the traditional high street, from sporting venues to arts centres, from railway termini to museums. Many see it as the epitome of Thatcher’s Britain, breeding acquisitive individualism and destroying our traditional manufacturing base. Others see it as a potential saviour of an ailing economy. Yet to date there has been no thorough analysis of this all-pervasive phenomenon, from its economic roots to its profound social effects. In Consuming Passion, Carl Gardner and Julie Sheppard have written the first overall study of the ‘retail revolution’ – a controversial and hard-hitting look at where retailing has come from, what it has achieved and where it is going. Key issues such as the role of design, the growth of the supermarket and shopping centre and the poor conditions of retail employment are all minutely examined. The book also discusses the very real pleasures that consumers gain from today’s enhanced shopping experience. The authors take an iconoclastic look at some of the powerful myths that have sprung up around retail: ‘the death of the high street’ scenario; the central role of credit; retailing as a major creator of employment; and the imminent possibility of ‘retail saturation’. A fascinating book for everyone who likes shopping – and even those who hate it. First published 1989.
The Therapeutic Nightmare

The Therapeutic Nightmare

John Abraham; Julie Sheppard

Earthscan Ltd
2009
nidottu
How do drugs get to the market? What controls are there and what procedures for monitoring their effects? And how adequate are the regulators in protecting public health when new drugs have serious side effects? The Therapeutic Nightmare tells the story of the sleeping pill Halcion - a story which is far from over. First marketed in the 1970s, Halcion has been taken by millions of patients around the world. For many years it has been associated with serious adverse effects such as amnesia, hallucinations, aggression and, in extreme cases, homicide. Thirteen years after its first release, it was banned by the British government. It remains on sale in the United States and many other countries. This book explains why patients have come to be exposed to Halcion's risks and examines the corporate interests of the manufacturers, the professional interests of the scientists and medical researchers and the interests of patients in safe and effective medication. It reveals how these contending forces shape the regulatory decision-making process about drug safety. As the number of new drugs and health products grows, a major challenge facing regulators and the medical profession is how to put the interests of public health decisively and consistently above the commercial interests of the drugs industry, while becoming more accountable to patient and consumer organizations.
The Therapeutic Nightmare

The Therapeutic Nightmare

John Abraham; Julie Sheppard

Earthscan Ltd
1999
sidottu
How do drugs get to the market? What controls are there and what procedures for monitoring their effects? And how adequate are the regulators in protecting public health when new drugs have serious side effects? The Therapeutic Nightmare tells the story of the sleeping pill Halcion - a story which is far from over. First marketed in the 1970s, Halcion has been taken by millions of patients around the world. For many years it has been associated with serious adverse effects such as amnesia, hallucinations, aggression and, in extreme cases, homicide. Thirteen years after its first release, it was banned by the British government. It remains on sale in the United States and many other countries. This book explains why patients have come to be exposed to Halcion's risks and examines the corporate interests of the manufacturers, the professional interests of the scientists and medical researchers and the interests of patients in safe and effective medication. It reveals how these contending forces shape the regulatory decision-making process about drug safety. As the number of new drugs and health products grows, a major challenge facing regulators and the medical profession is how to put the interests of public health decisively and consistently above the commercial interests of the drugs industry, while becoming more accountable to patient and consumer organizations.